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In this published article \[[@CR1]\], the efficacy data for the below outcomes were unfortunately not supplied based on the Full Analysis Set (FAS) at 3 and/or 6 months for specific outcomes under the statistical analysis plan (SAP). The SAP specified that the efficacy data should be based overall on the FAS at 3 months for the primary (with last observation carried forward, LOCF) and secondary (no LOCF) efficacy endpoints and 6 months for UK only (no LOCF). The amendments do not change the conclusions of the paper, and the corrected data are given below.

**Clinician and patient global impressions of change**

***Correction to CGI-C 6-month data (UK patients only)***

\[ ... \] For those UK patients (*n* = 95) who were also assessed at 6 months, 85.3% were judged as improved since commencing treatment (8.4% very much improved and 49.5% much improved) while 8.4% were judged as showing 'no change' and 6.4% as having worsened. \[ ... \]

Correction to Fig. [2](#Fig1){ref-type="fig"}b Fig. 2Global Impression of Change following 3 months treatment with opicapone 50 mg (a) investigator rated (CGI-C, *n* = 477, LOCF); (b) self-rated by the patient (PGI-C, *n* = 393)

**Rating scale outcomes**

***Correction to UPDRS analyses (**Table*** [***2***](#Tab1){ref-type="table"}***)***Table 2Rating scale assessmentsRating scale\[ ... \]UPDRS Part II (ADL during OFF); mean ± SD Baseline (*n* = 475)17.1 ± 7.0 3 months (*n* = 389)13.9 ± 6.8 Change from baseline (*n* = 389)− 3.0 ± 4.6*P* value vs. baseline\< 0.0001UPDRS Part III (motor scores during ON); mean ± SD Baseline (*n* = 476)26.5 ± 12.1 3 months (*n* = 391)21.5 ± 11.0 Change from baseline (*n* = 391)− 4.6 ± 8.1*P* value vs. baseline\< 0.0001\[...\]*NMSS* Non-motor symptom scale, *UPDRS* Unified Parkinson's Disease Rating Scale, *PDQ-8* Parkinson's Disease Questionnaire

N numbers for UPDRS Part II were 475 at baseline and 389 at 3 months (Visit 4); results of the change from baseline analysis remain unchanged. N numbers for UPDRS Part III were 476 at baseline and 391 at 3 months; results of the change from baseline analyses remain unchanged.

***Correction to*** Table [2](#Tab1){ref-type="table"}.

**Levodopa dosing**

***Correction to levodopa dosing***

After 3 months of treatment with opicapone, most patients remained on the same total daily levodopa frequency (77.1% had no change, 10.4% had an increase and 12.5% had a decrease in dosing frequency), resulting in an overall mean change of approximately − 10 mg/day. \[...\].

**Discussion**

***Correction to discussion***

\[ ... \] These judgements made by the investigators were corroborated by the patients themselves.

with 48.1% patients reporting they were much or very much improved after 3 months treatment with opicapone 50 mg. \[ ... \]

**Supplementary material**

***Correction to*** Supplementary Table 2

Results of the change from baseline in perceptual problems/hallucinations was updated to 0.0 ± 2.01. Results from all other analyses remain unchanged.

Supplementary Table 2 Change from baseline in NMSS domains NMSS domainMean ± SD\[ ... \]Perceptual problems/hallucinations Baseline0.8 ± 2.45 Change from baseline (*p* value)0.0 ± 2.01 (*p* = 0.7437)\[ ... \]
